The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Network imaging biomarkers: insights and clinical applications in Parkinson's disease
Abstract
Parkinson's disease presents several practical challenges: it can be difficult to distinguish from atypical parkinsonian syndromes, clinical ratings can be insensitive as markers of disease progression, and its non-motor manifestations are not readily assessed in animal models. These challenges, along with others, are beginning to be addressed by innovative imaging methods to characterise Parkinson's disease-specific functional networks across the whole brain and measure their expression in each patient. These signatures can help improve differential diagnosis, guide selection of patients for clinical trials, and quantify treatment responses and placebo effects in individual patients. The primary Parkinson's disease-related metabolic pattern has been replicated in multiple patient populations and used as an outcome measure in clinical trials. It can also be used as a predictor of near-term phenoconversion in prodromal syndromes, such as rapid eye movement sleep behaviour disorder. Functional network imaging holds great promise for future clinical use in the management of neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870
The neuroscience of placebo effects: connecting context, learning and health
Wager, T. D., & Atlas, L. Y. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3976 · Cited by 844
Connectivity Predicts deep brain stimulation outcome in Parkinson disease
Horn, A., Reich, M., Vorwerk, J., Li, N., Wenzel, G., Fang, Q., Schmitz‐Hübsch, T., Nickl, R., Kupsch, A., Volkmann, J., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24974 · Cited by 711
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
The psychosis spectrum in Parkinson disease
ffytche, D. H., Creese, B., Politis, M., Chaudhuri, K. R., Weintraub, D., Ballard, C., & Aarsland, D. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.200 · Cited by 355
Dopamine controls Parkinson's tremor by inhibiting the cerebellar thalamus
Dirkx, M. F., den Ouden, H. E. M., Aarts, E., Timmer, M. H. M., Bloem, B. R., Toni, I., & Helmich, R. C. (2017) · Brain · doi:10.1093/brain/aww331 · Cited by 152
Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease
Niethammer, M., Tang, C. C., LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Sarkar, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90133 · Cited by 124
Self-citationThe placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning
Frisaldi, E., Carlino, E., Zibetti, M., Barbiani, D., Dematteis, F., Lanotte, M., Lopiano, L., & Benedetti, F. (2017) · Movement Disorders · doi:10.1002/mds.27142 · Cited by 35
Cited by
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.001 · Cited by 323
Self-citationDynamic functional connectivity changes associated with dementia in Parkinson’s disease
Fiorenzato, E., Strafella, A. P., Kim, J., Schifano, R., Weis, L., Antonini, A., & Biundo, R. (2019) · Brain · doi:10.1093/brain/awz192 · Cited by 304
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Parkinson’s disease as a somato-cognitive action network disorder
Ren, J., Zhang, W., Dahmani, L., Gordon, E. M., Li, S., Zhou, Y., Long, Y., Huang, J., Zhu, Y., Guo, N., et al. (2026) · Nature · doi:10.1038/s41586-025-10059-1 · Cited by 55
Metadata
- Authors
- Schindlbeck, K. A., & Eidelberg, D.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 17
- Issue
- 7
- Pages
- 629-640
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2807819473
- Cited by
- 161
- References
- 10
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Network imaging biomarkers: insights and clinical applications in Parkinson's disease. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30169-8
- The paper
- Schindlbeck, K. A., & Eidelberg, D. (2018). Network imaging biomarkers: insights and clinical applications in Parkinson's disease. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30169-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.